---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020969"
form_type: "8-K"
ticker: "ALKS"
cik: "0001520262"
company_name: "Alkermes plc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T13:38:42.305293+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Alkermes reports Q3 GAAP loss of $0.39/share; plans to separate oncology business

## Summary
- Q3 total revenues $252.4M; net loss $64.0M; GAAP EPS -$0.39, non-GAAP EPS $0.02.
- Proprietary product net sales $199.4M: VIVITROL $96.5M (+9% YoY), ARISTADA $75.7M (+10%), LYBALVI $27.1M.
- Board approved exploration of separating oncology business into independent public company; expected completion H2 2023.
- Updated FY2022 guidance: total revenue $1.07B-$1.12B, non-GAAP EPS $0.15-$0.33; LYBALVI outlook raised to $88-$95M.
- One-time AMPYRA royalty reversal of ~$21.5M due to arbitration award.

## SEC filing metadata
- accession: 0000950170-22-020969
- form_type: 8-K
- ticker: ALKS
- cik: 0001520262
- company_name: Alkermes plc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/alks-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020969
- JSON: https://secwatch.observer/filing/0000950170-22-020969.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020969.txt

## Key facts
- Earnings Releases
  Alkermes plc. reported the third quarter of 2022 results: revenue $252.4 million, net income $64.0 million, EPS $0.39.
  - Period: the third quarter of 2022
  - Revenue: $252.4 million
  - Net income: $64.0 million
  - EPS: $0.39
  - Result: reported results
  source text: — Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0.02 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm
- Earnings Releases
  Alkermes plc. reported the year ending December 31, 2022 results: revenue $1,070 – $1,120. Guidance raised.
  - Period: the year ending December 31, 2022
  - Revenue: $1,070 – $1,120
  - Guidance: raised
  - Result: guidance update
  source text: to GAAP, except as otherwise noted. In millions (except per share amounts) Current 2022 Expectation (Provided 11/2/22) Prior 2022 Expectation (Provided 7/27/22) Total Revenue $1,070 – $1,120 $1,050 – $1,120 VIVITROL Net Sales $370 – $380 $365 – $385 ARISTADA Net Sales $300 – $310 $295 – $315 LYBALVI Net Sales $88 – $
  evidence_url: https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.